The patent for Levitra
(Vardenafil) does not expire until October 31, 2018. Sales for the maker of Levitra were about 250 million dollars in 2015. It is interesting that this is approximately the time when both Cialis (Tadalafil) and Viagra (Sildenafil) will have generic versions available.
Viagra’s patent protection ends in 2020. However, in an agreement with Teva pharmaceuticals, a generic will be available in December of this year. Only a single pharmaceutical company will make generic Viagra, called Sildenafil, so the pressure from competition will not be a factor driving down prices.
Viagra created income for Pfizer of more than 1.5 billion dollars in 2016.
In a related matter, Eli Lilly announced in July 2017, that Cialis would not come off patent protection in November of this year, as was expected. They arrived at a new, patent settlement with multiple, generic pharmaceutical companies that extended Lilly’s protection of Cialis until September 27, 2018. The agreement was reached with multiple pharmaceutical companies and there should be some downward pressure on price due to the competition–as opposed to the situation with Viagra.
First approved in 2003, it has been a major source of income creating 17 billion dollars of income for Lilly.
In 2016, Cialis netted Lilly nearly 1.5 billion dollars.
The price of Levitra generic will probably drop as many other drugs treating erectile dysfunction will be available as a generic at the same time.